Moderna, Inc.

NASDAQ Global Select
Back to all articles
Somewhat Bullish +35

Moderna Q2 EPS Estimate Lifted by Brookline Capital Markets

📈 Brookline Capital Markets raised Q2 2026 EPS estimate for Moderna to ($1.97) from ($1.98).

💰 Moderna reported Q2 revenue of $145.00 million, beating the consensus estimate of $102.93 million.

📉 The company posted a loss of ($1.97) per share for Q2 2026, beating the expected loss of ($2.03).

📊 Revenue grew by 2.1% year-over-year compared to the same quarter last year.

🏦 Institutional ownership stands at 75.33%, with recent purchases from MUFG Securities and EverSource Wealth Advisors.

💸 Insiders sold $5.928 million in stock over the last 90 days, primarily for tax withholding on equity awards.

📉 Q4 2026 EPS is forecasted at ($2.16) by Brookline Capital Markets.

🔬 Moderna's flagship product remains its mRNA-based COVID-19 vaccine with full approval in multiple jurisdictions.

📈 Stock price opened at $57.08, trading above the 200-day moving average of $52.87.

⚖️ The company maintains a strong liquidity position with a current ratio of 2.29 and zero debt-to-equity.

Bullish Signals
  • Moderna beat Q2 EPS estimates by $0.06, reporting ($1.97) versus the consensus of ($2.03).
  • Revenue significantly exceeded expectations at $145.00 million compared to the estimated $102.93 million.
  • The company achieved a 2.1% year-over-year revenue increase, demonstrating continued top-line growth.
  • Brookline Capital Markets raised its Q2 EPS estimate and provided positive forward guidance for FY2027.
  • Institutional investors like EverSource Wealth Advisors increased their positions by 148.3% in the second quarter.
  • The stock trades above its 200-day moving average, indicating sustained investor interest.
Risk Factors
  • Moderna reported a negative net margin of 141.43% and a negative return on equity of 28.30% for the quarter.
  • Insiders sold $5.9 million in shares over the last 90 days, including Director Noubar Afeyan reducing his stake by 70.24%.
  • The company continues to operate at a loss with a negative EPS of ($1.97) for Q2 2026.
Full Analysis
Brookline Capital Markets analyst L. Cann raised its Q2 2026 earnings per share (EPS) estimate for Moderna to ($1.97), a slight improvement from the previous forecast of ($1.98). The firm also provided forward guidance, projecting Q3 EPS at ($1.30), Q4 at ($2.16), full-year 2026 EPS at ($6.60), and FY2027 EPS at ($3.24). This update follows Moderna's recent earnings release where the company beat consensus estimates. Moderna reported Q2 2026 EPS of ($1.97), surpassing analyst expectations of ($2.03) by $0.06. Revenue for the quarter reached $145.00 million, significantly exceeding the consensus estimate of $102.93 million and representing a 2.1% year-over-year increase. Despite the revenue beat, the company posted a negative net margin of 141.43% and a negative return on equity of 28.30%, reflecting the high costs associated with its mRNA platform development. Institutional activity shows mixed signals regarding Moderna's stock. While several hedge funds like MUFG Securities EMEA and EverSource Wealth Advisors increased their stakes, insider selling remains notable. Over the last 90 days, insiders sold approximately $5.9 million in shares, including significant transactions by Director Noubar Afeyan and executive Shannon Thyme Klinger to cover tax obligations on vested equity awards.